Kaufman, Jonathan L.

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 988

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma

Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., O’Brien, T., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 908

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 861

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T.-W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., et al. (2009) · Science Signaling

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 784

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 487

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

Joseph, N. S., Kaufman, J. L., Dhodapkar, M. V., Hofmeister, C. C., Almaula, D. K., Heffner, L. T., Gupta, V. A., Boise, L. H., Lonial, S., & Nooka, A. K. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 238

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsNeutropenia and Cancer Infections

Cited by 212

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

Mailankody, S., Jakubowiak, A. J., Htut, M., Costa, L. J., Lee, K., Ganguly, S., Kaufman, J. L., Siegel, D. S. D., Bensinger, W., Cota, M., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 126

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

Mazumder, A., Kaufman, J., Niesvizky, R., Lonial, S., Vesole, D., & Jagannath, S. (2008) · Leukemia

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 126

Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma

Gupta, V. A., Matulis, S. M., Conage-Pough, J. E., Nooka, A. K., Kaufman, J. L., Lonial, S., & Boise, L. H. (2017) · Blood

Multiple Myeloma Research and TreatmentsCell death mechanisms and regulation

Cited by 113

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., et al. (2020) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 112

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience

Scott, S. A., Marin, E. M., Maples, K. T., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Kaufman, J. L., Lonial, S., & Nooka, A. K. (2023) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 63

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 54

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

Robinson, M. H., Villa, N. Y., Jaye, D. L., Nooka, A. K., Duffy, A., McCachren, S. S., Manalo, J., Switchenko, J. M., Barnes, S., Potdar, S., et al. (2023) · Journal of Clinical Investigation

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 48

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Lonial, S., Jacobus, S. J., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A., Buadi, F., O'Brien, T. E., Matous, J., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 28

Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma

Cho, H. J., Costa, L. J., Davies, F. E., Neparidze, N., Vij, R., Feng, Y., Teterina, A., Wassner Fritsch, E., Wenger, M., & Kaufman, J. L. (2018) · Blood

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 21

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

Cani, L., Scott, S. A., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Lonial, S., Nooka, A. K., & Kaufman, J. L. (2024) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 9

Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma

Potdar, S. V., Kapadia, S., Azeem, M. I., Radzievski, R., Lakhani, K., Joseph, N. S., Kaufman, J. L., Hofmeister, C. C., Gupta, V. A., Lonial, S., et al. (2025) · Blood Advances

Multiple Myeloma Research and TreatmentsT-cell and B-cell Immunology

Cited by 7